Header Logo

Connection

Gesine Meyer-Rath to HIV Infections

Back to Details
This is a "connection" page, showing publications Gesine Meyer-Rath has written about HIV Infections.
Gesine Meyer-Rath
Connection Strength
5,570
HIV Infections
  1. Optimising HIV spending in eastern Europe and central Asia. Lancet HIV. 2024 Oct; 11(10):e654-e655.
    View in: PubMed
    Score: 0,259
  2. What will it take for an injectable ARV to change the face of the HIV epidemic in high-prevalence countries? Considerations regarding drug costs and operations. J Int AIDS Soc. 2023 07; 26 Suppl 2:e26106.
    View in: PubMed
    Score: 0,239
  3. Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and threshold analysis. Lancet HIV. 2022 12; 9(12):e857-e867.
    View in: PubMed
    Score: 0,229
  4. Cost and cost-effectiveness of dolutegravir-based antiretroviral regimens: an economic evaluation of a clinical trial. AIDS. 2021 12 15; 35(Suppl 2):S173-S182.
    View in: PubMed
    Score: 0,215
  5. Role of data from cost and other economic analyses in healthcare decision-making for HIV, TB and sexual/reproductive health programmes in South Africa. Health Policy Plan. 2021 Nov 11; 36(10):1545-1551.
    View in: PubMed
    Score: 0,213
  6. Getting resources to those who need them: the evidence we need to budget for underserved populations in sub-Saharan Africa. J Int AIDS Soc. 2021 07; 24 Suppl 3:e25707.
    View in: PubMed
    Score: 0,208
  7. The cost and intermediary cost-effectiveness of oral HIV self-test kit distribution across 11 distribution models in South Africa. BMJ Glob Health. 2021 07; 6(Suppl 4).
    View in: PubMed
    Score: 0,208
  8. The cost effectiveness and optimal configuration of HIV self-test distribution in South Africa: a model analysis. BMJ Glob Health. 2021 07; 6(Suppl 4).
    View in: PubMed
    Score: 0,208
  9. The impact of self-selection based on HIV risk on the cost-effectiveness of preexposure prophylaxis in South Africa. AIDS. 2020 05 01; 34(6):883-891.
    View in: PubMed
    Score: 0,192
  10. Optimal HIV testing strategies for South Africa: a model-based evaluation of population-level impact and cost-effectiveness. Sci Rep. 2019 09 02; 9(1):12621.
    View in: PubMed
    Score: 0,183
  11. The per-patient costs of HIV services in South Africa: Systematic review and application in the South African HIV Investment Case. PLoS One. 2019; 14(2):e0210497.
    View in: PubMed
    Score: 0,177
  12. Targeting the right interventions to the right people and places: the role of geospatial analysis in HIV program planning. AIDS. 2018 05 15; 32(8):957-963.
    View in: PubMed
    Score: 0,168
  13. Changing the South African national antiretroviral therapy guidelines: The role of cost modelling. PLoS One. 2017; 12(10):e0186557.
    View in: PubMed
    Score: 0,161
  14. Revealed willingness-to-pay versus standard cost-effectiveness thresholds: Evidence from the South African HIV Investment Case. PLoS One. 2017; 12(10):e0186496.
    View in: PubMed
    Score: 0,161
  15. Cost-effectiveness of early identification of HIV infection. Lancet HIV. 2017 10; 4(10):e431-e432.
    View in: PubMed
    Score: 0,159
  16. Designing an optimal HIV programme for South Africa: Does the optimal package change when diminishing returns are considered? BMC Public Health. 2017 01 31; 17(1):143.
    View in: PubMed
    Score: 0,153
  17. Prospects for HIV control in South Africa: a model-based analysis. Glob Health Action. 2016; 9:30314.
    View in: PubMed
    Score: 0,147
  18. The Impact of Company-Level ART Provision to a Mining Workforce in South Africa: A Cost-Benefit Analysis. PLoS Med. 2015 Sep; 12(9):e1001869.
    View in: PubMed
    Score: 0,139
  19. Rates and cost of hospitalization before and after initiation of antiretroviral therapy in urban and rural settings in South Africa. J Acquir Immune Defic Syndr. 2013 Mar 01; 62(3):322-328.
    View in: PubMed
    Score: 0,117
  20. Cost and outcomes of paediatric antiretroviral treatment in South Africa. AIDS. 2013 Jan 14; 27(2):243-50.
    View in: PubMed
    Score: 0,116
  21. Cost and resource use of patients on antiretroviral therapy in the urban and semiurban public sectors of South Africa. J Acquir Immune Defic Syndr. 2012 Nov 01; 61(3):e25-32.
    View in: PubMed
    Score: 0,114
  22. HIV treatment as prevention: modelling the cost of antiretroviral treatment--state of the art and future directions. PLoS Med. 2012; 9(7):e1001247.
    View in: PubMed
    Score: 0,112
  23. The cost-effectiveness of herpes simplex virus-2 suppressive therapy with daily aciclovir for delaying HIV disease progression among HIV-1-infected women in South Africa. Sex Transm Dis. 2011 May; 38(5):401-9.
    View in: PubMed
    Score: 0,103
  24. The cost effectiveness of integrated care for people living with HIV including antiretroviral treatment in a primary health care centre in Bujumbura, Burundi. AIDS Care. 2009 Nov; 21(11):1388-94.
    View in: PubMed
    Score: 0,093
  25. Reaching priority populations with different HIV self-testing distribution models in South Africa: an analysis of programme data. BMC Infect Dis. 2025 Feb 25; 22(Suppl 1):981.
    View in: PubMed
    Score: 0,067
  26. Transgender-Specific Differentiated HIV Service Delivery Models in the South African Public Primary Health Care System (Jabula Uzibone): Protocol for an Implementation Study. JMIR Res Protoc. 2024 Sep 13; 13:e64373.
    View in: PubMed
    Score: 0,065
  27. Future HIV epidemic trajectories in South Africa and projected long-term consequences of reductions in general population HIV testing: a mathematical modelling study. Lancet Public Health. 2024 Apr; 9(4):e218-e230.
    View in: PubMed
    Score: 0,063
  28. Costs of distributing HIV self-testing kits in Eswatini through community and workplace models. BMC Infect Dis. 2024 Feb 29; 22(Suppl 1):976.
    View in: PubMed
    Score: 0,063
  29. The potential benefits of long-acting injectable cabotegravir in pregnant and breastfeeding women and their infants. AIDS. 2024 03 15; 38(4):589-594.
    View in: PubMed
    Score: 0,062
  30. A quantitative assessment of the consistency of projections from five mathematical models of the HIV epidemic in South Africa: a model comparison study. BMC Public Health. 2023 10 27; 23(1):2119.
    View in: PubMed
    Score: 0,061
  31. Acceptability, feasibility and cost of point of care testing for sexually transmitted infections among South African adolescents where syndromic management is standard of care. BMC Health Serv Res. 2023 Oct 10; 23(1):1078.
    View in: PubMed
    Score: 0,061
  32. Secondary distribution of HIV self-test kits by HIV index and antenatal care clients: implementation and costing results from the STAR Initiative in South Africa. BMC Infect Dis. 2023 Jun 01; 22(Suppl 1):971.
    View in: PubMed
    Score: 0,059
  33. Cost and outcomes of routine HIV care and treatment: public and private service delivery models covering low-income earners in South Africa. BMC Health Serv Res. 2023 Mar 11; 23(1):240.
    View in: PubMed
    Score: 0,059
  34. Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study. Lancet HIV. 2023 04; 10(4):e254-e265.
    View in: PubMed
    Score: 0,058
  35. Cost-effectiveness of voluntary medical male circumcision for HIV prevention across sub-Saharan Africa: results from five independent models. Lancet Glob Health. 2023 Feb; 11(2):e244-e255.
    View in: PubMed
    Score: 0,058
  36. Transmission reduction, health benefits, and upper-bound costs of interventions to improve retention on antiretroviral therapy: a combined analysis of three mathematical models. Lancet Glob Health. 2022 09; 10(9):e1298-e1306.
    View in: PubMed
    Score: 0,056
  37. Cost-effectiveness of easy-access, risk-informed oral pre-exposure prophylaxis in HIV epidemics in sub-Saharan Africa: a modelling study. Lancet HIV. 2022 05; 9(5):e353-e362.
    View in: PubMed
    Score: 0,055
  38. Reduction in initiations of HIV treatment in South Africa during the COVID pandemic. BMC Health Serv Res. 2022 Mar 31; 22(1):428.
    View in: PubMed
    Score: 0,055
  39. Costs of integrating HIV self-testing in public health facilities in Malawi, South Africa, Zambia and Zimbabwe. BMJ Glob Health. 2021 07; 6(Suppl 4).
    View in: PubMed
    Score: 0,052
  40. Modelling costs of community-based HIV self-testing programmes in Southern Africa at scale: an econometric cost function analysis across five countries. BMJ Glob Health. 2021 07; 6(Suppl 4).
    View in: PubMed
    Score: 0,052
  41. Potential Impact and Cost-Effectiveness of Condomless-Sex-Concentrated PrEP in KwaZulu-Natal Accounting for Drug Resistance. J Infect Dis. 2021 04 23; 223(8):1345-1355.
    View in: PubMed
    Score: 0,051
  42. Using HIV self-testing to increase the affordability of community-based HIV testing services. AIDS. 2020 11 15; 34(14):2115-2123.
    View in: PubMed
    Score: 0,050
  43. Cost-per-diagnosis as a metric for monitoring cost-effectiveness of HIV testing programmes in low-income settings in southern Africa: health economic and modelling analysis. J Int AIDS Soc. 2019 07; 22(7):e25325.
    View in: PubMed
    Score: 0,045
  44. Cost-Effectiveness of Cervical Cancer Screening in Women Living With HIV in South Africa: A Mathematical Modeling Study. J Acquir Immune Defic Syndr. 2018 10 01; 79(2):195-205.
    View in: PubMed
    Score: 0,043
  45. The cost-effectiveness of multi-purpose HIV and pregnancy prevention technologies in South Africa. J Int AIDS Soc. 2018 03; 21(3).
    View in: PubMed
    Score: 0,041
  46. Effect of eliminating CD4-count thresholds on HIV treatment initiation in South Africa: An empirical modeling study. PLoS One. 2017; 12(6):e0178249.
    View in: PubMed
    Score: 0,039
  47. Evidence for scaling up HIV treatment in sub-Saharan Africa: A call for incorporating health system constraints. PLoS Med. 2017 02; 14(2):e1002240.
    View in: PubMed
    Score: 0,038
  48. Citizenship status and engagement in HIV care: an observational cohort study to assess the association between reporting a national ID number and retention in public-sector HIV care in Johannesburg, South Africa. BMJ Open. 2017 01 24; 7(1):e013908.
    View in: PubMed
    Score: 0,038
  49. Attrition through multiple stages of pre-treatment and ART HIV care in South Africa. PLoS One. 2014; 9(10):e110252.
    View in: PubMed
    Score: 0,033
  50. Cost-effectiveness of tenofovir gel in urban South Africa: model projections of HIV impact and threshold product prices. BMC Infect Dis. 2014 Jan 09; 14:14.
    View in: PubMed
    Score: 0,031
  51. Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models. Lancet Glob Health. 2014 Jan; 2(1):e23-34.
    View in: PubMed
    Score: 0,031
  52. Impact and costs of algorithms for the diagnosis of adults with pulmonary tuberculosis in South Africa. S Afr Med J. 2013 Jul; 103(7):436.
    View in: PubMed
    Score: 0,030
  53. Diagnosing Xpert MTB/RIF negative TB: impact and cost of alternative algorithms for South Africa. S Afr Med J. 2013 Jan 14; 103(2):101-6.
    View in: PubMed
    Score: 0,029
  54. Feasibility, yield, and cost of active tuberculosis case finding linked to a mobile HIV service in Cape Town, South Africa: a cross-sectional study. PLoS Med. 2012; 9(8):e1001281.
    View in: PubMed
    Score: 0,028
  55. Good treatment outcomes among foreigners receiving antiretroviral therapy in Johannesburg, South Africa. Int J STD AIDS. 2009 Dec; 20(12):858-62.
    View in: PubMed
    Score: 0,023
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.